• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Redefining the treatment paradigm for multiple myeloma.

作者信息

Gay Francesca, Mina Roberto

机构信息

Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, 10126 Torino, Italy.

Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, 10126 Torino, Italy.

出版信息

Lancet Oncol. 2019 Jun;20(6):743-744. doi: 10.1016/S1470-2045(19)30295-5. Epub 2019 May 13.

DOI:10.1016/S1470-2045(19)30295-5
PMID:31097404
Abstract
摘要

相似文献

1
Redefining the treatment paradigm for multiple myeloma.重新定义多发性骨髓瘤的治疗模式。
Lancet Oncol. 2019 Jun;20(6):743-744. doi: 10.1016/S1470-2045(19)30295-5. Epub 2019 May 13.
2
Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.来那度胺用于复发难治性骨髓瘤患者：既往对硼替佐米和沙利度胺的反应对治疗疗效的影响。比利时一项医疗需求项目的结果
Acta Clin Belg. 2011 Sep-Oct;66(5):371-5. doi: 10.2143/ACB.66.5.2062589.
3
The emerging role of novel therapies for the treatment of relapsed myeloma.新型疗法在复发骨髓瘤治疗中的新兴作用。
J Natl Compr Canc Netw. 2007 Feb;5(2):149-62. doi: 10.6004/jnccn.2007.0015.
4
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.硼替佐米联合来那度胺和地塞米松与单纯来那度胺和地塞米松治疗新诊断的无立即自体干细胞移植意向的骨髓瘤患者（SWOG S0777）：一项随机、开放标签的3期试验
Lancet. 2017 Feb 4;389(10068):519-527. doi: 10.1016/S0140-6736(16)31594-X. Epub 2016 Dec 23.
5
Lenalidomide: new drug. Myeloma: many questions remain unanswered.来那度胺：新药。骨髓瘤：诸多问题仍未得到解答。
Prescrire Int. 2008 Dec;17(98):230-2.
6
[Successful treatment with thalidomide-combined therapy in an amyloidosis-complicated multiple myeloma patient refractory to bortezomib, lenalidomide, and pomalidomide].[沙利度胺联合疗法成功治疗一名对硼替佐米、来那度胺和泊马度胺难治的淀粉样变性合并多发性骨髓瘤患者]
Rinsho Ketsueki. 2018;59(3):275-280. doi: 10.11406/rinketsu.59.275.
7
[Treatment of multiple myeloma with lenalidomide and bortezomib combination therapy].来那度胺与硼替佐米联合疗法治疗多发性骨髓瘤
Nihon Rinsho. 2015 Jan;73(1):130-6.
8
Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials.单克隆抗体与组蛋白去乙酰化酶抑制剂联合硼替佐米或来那度胺加地塞米松治疗复发或难治性多发性骨髓瘤：随机对照试验的间接比较荟萃分析。
J Immunol Res. 2018 Jun 27;2018:7646913. doi: 10.1155/2018/7646913. eCollection 2018.
9
Activity and toxicity profiles of the combinations bendamustine-lenalidomide-dexamethasone and bendamustine-bortezomib-dexamethasone for advanced stage multiple myeloma.苯达莫司汀-来那度胺-地塞米松及苯达莫司汀-硼替佐米-地塞米松联合方案用于晚期多发性骨髓瘤的活性及毒性特征
Leuk Lymphoma. 2014 May;55(5):1191-3. doi: 10.3109/10428194.2013.820289. Epub 2013 Aug 13.
10
[Pomalidomide in the treatment of relapsed and refractory multiple myeloma].泊马度胺治疗复发难治性多发性骨髓瘤
Klin Onkol. 2014;27(5):318-25. doi: 10.14735/amko2014318.

引用本文的文献

1
The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance.BLM 解旋酶是多发性骨髓瘤中涉及复制应激存活和耐药性的新的治疗靶点。
Front Immunol. 2022 Dec 9;13:983181. doi: 10.3389/fimmu.2022.983181. eCollection 2022.
2
[Research progress of brain-derived microparticles on microglia polarization in radiation-induced brain injury of head and neck tumors].脑源性微粒对头颈部肿瘤放射诱导脑损伤中微胶质细胞极化的研究进展
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2021 Jan 5;35(1):88-91. doi: 10.13201/j.issn.2096-7993.2021.01.023.